Page last updated: 2024-10-23

benserazide and Body Weight

benserazide has been researched along with Body Weight in 9 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
" The present study has explored the influence of acute tianeptine pretreatment upon corticosterone release and body weight loss following L-5-hydroxytryptophan (5-HTP) administration in conscious rats."7.68Differential effects of the novel antidepressant tianeptine on L-5-hydroxytryptophan (5-HTP)-elicited corticosterone release and body weight loss. ( Baudrie, V; Broqua, P; Chaouloff, F, 1992)
" The present study has explored the influence of acute tianeptine pretreatment upon corticosterone release and body weight loss following L-5-hydroxytryptophan (5-HTP) administration in conscious rats."3.68Differential effects of the novel antidepressant tianeptine on L-5-hydroxytryptophan (5-HTP)-elicited corticosterone release and body weight loss. ( Baudrie, V; Broqua, P; Chaouloff, F, 1992)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19907 (77.78)18.7374
1990's2 (22.22)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bender, DA1
Ulm, G1
Gerdes, U1
Lehmann, K1
Jensen, EW1
Eldrup, E1
Kelbaek, H1
Nielsen, SL1
Christensen, NJ1
Schlosberg, AJ1
Harvey, JA2
Yunger, LM1
Broqua, P1
Baudrie, V1
Chaouloff, F1
MiƱano, FJ1
Myers, RD1
Rondot, P1
Dumas, RJ1
Derkach, P1
Larochelle, L1
Bieger, D1
Hornykiewicz, O1

Other Studies

9 other studies available for benserazide and Body Weight

ArticleYear
Effects of benserazide, carbidopa and isoniazid administration on tryptophan-nicotinamide nucleotide metabolism in the rat.
    Biochemical pharmacology, 1980, Aug-01, Volume: 29, Issue:15

    Topics: Animals; Benserazide; Body Weight; Carbidopa; Diet; Hydrazines; Isoniazid; Liver; Male; Niacinamide;

1980
Response to Sinemet 25/100 in Parkinson's disease.
    Advances in neurology, 1984, Volume: 40

    Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Hum

1984
Venous plasma noradrenaline increases with age: correlation to total blood volume and long-term smoking habits.
    Clinical physiology (Oxford, England), 1993, Volume: 13, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Aging; Benserazide; Blood Volume; Bo

1993
Effects of L-dopa and L-5-hydroxytryptophan on locomotor activity of the rat after selective or combined destruction of central catecholamine and serotonin neurons.
    The Journal of pharmacology and experimental therapeutics, 1979, Volume: 211, Issue:2

    Topics: 5-Hydroxytryptophan; Animals; Benserazide; Body Weight; Catecholamines; Humans; Levodopa; Locomotion

1979
Behavioral effects of L-5-hydroxytryptophan after destruction of ascending serotonergic pathways in the rat: the role of catecholaminergic neurons.
    The Journal of pharmacology and experimental therapeutics, 1976, Volume: 196, Issue:2

    Topics: Animals; Behavior, Animal; Benserazide; Biogenic Amines; Body Weight; Catecholamines; Electroshock;

1976
Differential effects of the novel antidepressant tianeptine on L-5-hydroxytryptophan (5-HTP)-elicited corticosterone release and body weight loss.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1992, Volume: 2, Issue:2

    Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Benserazide; Body Weight; Corticosterone; Male;

1992
Inhibition of brain dopa-decarboxylase by RO 4-4602 infused ICV blocks alcohol drinking induced in rats by cyanamide.
    Psychopharmacology, 1989, Volume: 98, Issue:2

    Topics: Alcohol Drinking; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Body Weight; B

1989
[Dopamine and abnormal movements].
    Revue neurologique, 1972, Volume: 127, Issue:1

    Topics: Benserazide; Body Weight; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Electro

1972
L-DOPA-chlorpromazine antagonism on running activity in mice.
    Canadian journal of physiology and pharmacology, 1974, Volume: 52, Issue:1

    Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Body Weight; Chlorpromazine; Dih

1974